Schering-Plough Corp. is fighting what is sees as an attempt to horn in on profits generated by its top-selling Claritin allergy drug. Schering filed a patent infringement suit last week in Delaware federal court against Copley Pharmaceuticals Inc. over Copley's bid to sell a generic version of Claritin in syrup form. The suit wants Copley barred from selling the generic drug and to pay unspecified tremble damages for the infringement.
March 23, 1999 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Schering-Plough Corp. apparently is allergic to anothercompany’s attempts to horn in on profits generated by its top-sellingClaritin allergy drug.
That’s why it filed a patent infringement suit in federal court inWilmington against Copley Pharmaceuticals Inc. last week over Copley’sbid to sell a generic version of Claritin, which generated $2.3 billionin sales in 1998, making Claritin the world’s best-sellingantihistamine.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
